• PharmaEssentia’s ropeginterferon alfa-2b secured approval for essential thrombocythemia in the US and China.
• Taiwan and Japan also cleared the treatment for the blood cancer.
• The indication remains unapproved in Europe, where licensing partner AOP handles regulatory submissions and commercialization.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PharmaEssentia Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202611030549BIZWIRE_USPR_____20261103_BW812674) on November 03, 2026, and is solely responsible for the information contained therein.